Excellergy focuses on creating a new class of allergic Effector Cell Response Inhibitors (ECRIs) designed to block the cellular mechanisms that drive allergic reactions. The company, which publicly launched alongside its financing, is building a pipeline of first-in-class therapies aimed at transforming allergy treatment. Proceeds from its initial funding will be used to advance its lead ECRI candidates into first-in-human clinical studies. Management has not yet disclosed product timelines or commercial metrics, but the substantial Series A raise underscores strong investor confidence in the science. Backers highlight the potential for Excellergy’s platform to address a broad range of allergic diseases where current options are limited. The company positions itself to move rapidly through early clinical development thanks to the sizable capital infusion. No revenue or user metrics have been released to date.

Total raised

$70M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2025